Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)
Annals of Oncology, 10/21/09

Niwiska A et al. – HER2-positive and triple-negative breast cancers have special predilection for metastases to the brain. Survival from brain metastases depended on performance status and the use of systemic treatment.

Methods

222 breast cancer patients with brain metastasis divided into three biological subgroups
Propensity of biological subtypes for metastases to brain and survivals depending on biological subtype, recursive partitioning analysis of Radiation Therapy Oncology Group (RPA RTOG) prognostic class and use of systemic treatment after whole-brain radiotherapy assessed

Results

Rate of patients with triple-negative, human epidermal growth factor receptor 2 (HER2)-positive and luminal breast cancer with brain metastases was 28%, 53% and 19%, respectively
Median survival from brain metastases in triple-negative, HER2-positive and luminal subtype 3.7, 9 and 15 months, respectively
Median survival from brain metastases in RPA RTOG prognostic class I, II and III was 15, 11 and 3 months, respectively
In luminal and in triple-negative subtype, systemic therapy prolonged survival from 3 to 14 months and from 3 to 4 months, respectively
In HER2-positive subtype, median survival without further treatment, after chemotherapy and after chemotherapy with targeted therapy 3, 8 and 11 months, respectively

<< Previous
Polymorphisms in the nucleotide excision repair gene ERCC2/XPD...

Next >>
Reoperative sentinel lymph node biopsy in ipsilateral breast...